Bicycle aims to follow in Padcev’s slipstream
A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.
ASCO 2023 – Behind Astellas comes Elevation
Elevation’s anti-Claudin18.2 antibody-drug conjugate generates some justified optimism, but Zai Lab’s zolbetuximab challenger is out of luck.
